Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical, Inc. (NASDAQ:CLSD) will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time. The company's President and CEO, George Lasezkay, and Chief Medical Officer, Thomas A. Ciulla, will discuss Clearside's innovative SCS injection platform that targets therapies to the back of the eye. This platform aims to improve vision preservation and enhance treatment delivery for sight-threatening diseases. Live and archived webcasts will be available on their website.

Clearside Biomedical (NASDAQ:CLSD) announced favorable safety results and efficacy data from its CLS-AX OASIS Phase 1/2a trial in patients with wet AMD. The company is advancing to a larger Phase 2 trial, backed by new funding of up to $65 million from a Royalty Interest Purchase Agreement with HealthCare Royalty Partners. Despite a decline in third-quarter 2022 revenue to $0.3 million from $3.1 million in 2021, R&D expenses decreased to $4.6 million. The net loss for Q3 2022 was $7.8 million, compared to a loss of $4.9 million the previous year. Cash reserves of $53.4 million are projected to extend into 2024.

Clearside Biomedical (Nasdaq:CLSD) reported positive outcomes from its OASIS Phase 1/2a clinical trial for CLS-AX, an injectable suspension aimed at treating neovascular age-related macular degeneration (wet AMD). The study achieved its primary safety endpoint, demonstrating that all doses were well-tolerated with no serious adverse events. Results showed significant durability, with an 88% injection-free rate in Cohorts 3 and 4 at Month 5. The company plans to initiate a Phase 2 trial in Q1 2023 and expects to release final 6-month data from the Extension Study soon.

Clearside Biomedical (NASDAQ:CLSD) will host a conference call on November 9, 2022, at 8:30 a.m. ET to discuss results from its OASIS Phase 1/2a clinical trial of CLS-AX for treating wet AMD patients. The company will also release its financial results for Q3 2022 on the same day. The conference will include key opinion leader Arshad Khanani, M.D., and both live and archived webcasts will be available for investors. Clearside specializes in innovative therapy delivery to the eye through its proprietary SCS Microinjector.

Clearside Biomedical, Inc. (NASDAQ:CLSD) will report its third quarter 2022 financial results on November 9, 2022, before market open. Management will host a conference call at 8:30 a.m. ET to discuss results and provide corporate updates. The call can be accessed at (888) 506-0062 (domestic) or (973) 528-0011 (international) with conference code: 111701. Clearside specializes in innovative therapy delivery to the eye, utilizing its proprietary SCS Microinjector.

Clearside Biomedical (CLSD) has presented promising clinical data regarding its SCS Microinjector, showcased at the American Academy of Ophthalmology 2022 meeting. The data indicate a favorable safety profile and efficacy across various ophthalmic treatments delivered through the suprachoroidal space (SCS). Notably, trials involving gene therapy and small molecules are progressing, with four therapies and six clinical trials currently underway. The interim results from partnered programs demonstrated statistically significant tumor control rates and visual acuity preservation, reinforcing Clearside's leadership in SCS delivery technology.

Clearside Biomedical (NASDAQ: CLSD) announces that clinical trial data for the CLS-AX program related to wet AMD will be reported in November 2022. Dr. Thomas A. Ciulla will present a corporate overview at the Eyecelerator conference on September 29, 2022, during the American Academy of Ophthalmology's Annual Meeting. The OASIS Phase 1/2a trial aims to evaluate the benefits of combining pan-VEGF inhibition with targeted delivery methods using Clearside’s proprietary SCS Microinjector. This highlights the potential advancements in treating sight-threatening eye diseases.

Clearside Biomedical, Inc. (NASDAQ:CLSD) will have its Chief Medical Officer, Thomas A. Ciulla, present a company overview and participate as a panelist on August 31, 2022, at the Ophthalmology Futures Retina Forum 2022. Dr. Ciulla will discuss alternatives to intravitreal drug delivery for posterior segment diseases. The forum aims to connect various stakeholders in ophthalmology to foster innovation in eye care. Clearside is known for its revolutionary SCS injection platform, enabling targeted delivery of therapies for sight-threatening diseases.

Clearside Biomedical, Inc. (NASDAQ:CLSD) reported Q2 2022 results with revenues of $384,000, down from $780,000 in Q2 2021. R&D expenses increased to $5.4 million, contributing to a net loss of $7.8 million ($0.13 per share), compared to a net loss of $6.1 million ($0.11 per share) in the prior year. The company completed dosing in two cohorts of the OASIS Phase 1/2a trial for CLS-AX and secured a non-dilutive financing agreement with HealthCare Royalty for up to $65 million to support clinical development. CLS-AX data is expected in November 2022.